Soft­Bank leads $150M round in­to Dew­point as con­den­sate biotech nears clin­ic

In an­oth­er mar­ket, Dew­point Ther­a­peu­tics may have gone pub­lic about now and raised a prince­ly sum.

Al­though they’re still around two years from hu­man tri­als, the biotech al­ready has blue-chip VC back­ers, three Big Phar­ma part­ner­ships, and a com­pelling sto­ry about be­ing the first and biggest en­trant to a new field of bi­ol­o­gy. But Wall Street isn’t buy­ing much of any­thing these days.

So Dew­point will have to set­tle for the next best thing: a ven­ture cap­i­tal firm that of­ten acts as if it has as much mon­ey as Wall Street — Soft­Bank.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN